Investors

Data Provided by Refinitiv. Minimum 15 minutes delayed.

DPX-Survivac, a novel T cell immunotherapy, induces robust T cell responses in advanced ovarian cancer with significant anti-tumor efficacy

Feb 6, 2020

Supporting Materials